IntelliPharmaCeutics Intl Inc (USA)  

(Public, NASDAQ:IPCI)   Watch this stock  
Find more results for IPCI
2.17
+0.05 (2.36%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.10 - 2.23
52 week 1.45 - 3.35
Open 2.10
Vol / Avg. 45,462.00/104,704.00
Mkt cap 68.17M
P/E     -
Div/yield     -
EPS -0.36
Shares 30.39M
Beta 1.11
Inst. own 0%

Key stats and ratios

Q1 (Feb '17) 2016
Net profit margin -161.16% -451.43%
Operating margin -149.66% -438.41%
EBITD margin - -421.27%
Return on average assets -100.23% -153.70%
Return on average equity -803.52% -2073.14%
Employees 52 -
CDP Score - -

Address

30 Worcester Rd
ETOBICOKE, ON M9W 5X2
Canada
+1-416-7983001 (Phone)
+1-416-7983007 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Officers and directors

Isa Odidi Ph.D. Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Amina Odidi Ph.D. President, Chief Operating Officer, Director
Bio & Compensation  - Reuters
Domenic Della Penna Chief Financial Officer
Bio & Compensation  - Reuters
John N. Allport Vice President - Legal Affairs and Licensing, Secretary, Director
Bio & Compensation  - Reuters
Patrick N. Yat Ph.D. Vice President - Pharmaceutical Analysis and Chemistry
Bio & Compensation  - Reuters
Kenneth Keirstead Independent Director
Bio & Compensation  - Reuters
Bahadur Madhani Independent Director
Bio & Compensation  - Reuters
Eldon R. Smith M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters